Venus Remedies Ltd has announced that the company has launched the third research product after the completion of phase III clinical trials and approval by DCGI.
This innovative product, an FDC of Cephalosporin with Aminoglycoside for the treatment of HAP and CAP has been launched for the first time globally under strategic marketing and distribution agreement with Ipca Laboratories and Themis Medicare all over India and shall be catering to multi-specialty hospitals and trauma care centres. This shall not only provide instant relief to the patients, but also be a remedy readily available with the doctors for treatment of HAP/CAP and at the same time expected to be a volume builder to sales of the company. On the basis of the results of the clinical trial, the company expects this formulation to penetrate the markets with great speed due to its higher efficacy and economy of treatment, a company release stated.
This unique combination of a Cephalosporin with Aminoglycoside developed by the research wing of the company is a super specialty product. The innovative drug shall help in providing instant remedy for hospital acquired Pneumonia, which can be fatal for any patient in intensive care. The synergistic affect of Cefepime and Amikacin shall ensure that the second antibiotic will quickly kill the bacteria harboring mutations that confer resistance to one antibiotic before additional resistance-conferring mutations have an opportunity to occur.
This original research product of the company, the patent for which is under process, has been launched in a market estimated to be worth INR 400 crores and is projected to gain at least 10 per cent market share by the end of 2007-08. This product having a worldwide market for approx. USD 800 million has attracted the attention of many multi national companies and talks are under way to provide the best platform for its global placement.